Perrigo | PRGO - Assets


Perrigo reported $7.98B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Abbott USD 110.43B 23.72B Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Corcept Therapeutics USD 814.88M 21.77M Mar/2026
Dr.Reddys Laboratories INR 581.23B 18.34B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Nestle CHF 127.15B 2.97B Dec/2025
Pacira USD 1.21B 56.38M Mar/2026
Perrigo USD 7.98B 551.9M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Phibro Animal Health USD 1.45B 39.56M Mar/2026
Prestige Brands USD 3.49B 430K Mar/2026
Reckitt Benckiser GBP 25.3B 1.11B Dec/2024
Sanofi EUR 128.02B 1.22B Mar/2026
Supernus Pharmaceuticals USD 1.5B 48.08M Mar/2026
Teva Pharmaceutical Industries USD 40.04B 708M Mar/2026
Xeris Pharmaceuticals USD 392.01M 8.49M Mar/2026
Zoetis USD 15.15B 313M Mar/2026